Osamu Honmou

StemCell Institute Inc. is a prominent Japanese biotechnology company specializing in regenerative medicine and stem cell banking, founded by Professor Osamu Honmou of Sapporo Medical University. The company operates Japan's largest private cord blood bank and provides comprehensive services for the collection, processing, and storage of various stem cell types, including umbilical cord and adipose-derived cells. Its research and development efforts are centered on mesenchymal stem cell (MSC) therapies for neurological disorders, leveraging technology that led to the approval of Stemirac, the world's first MSC product for spinal cord injury. StemCell Institute plays a critical role in the regenerative medicine ecosystem in Japan by bridging academic research with commercial cell processing and therapeutic applications. The company is publicly traded on the Tokyo Stock Exchange and maintains strategic collaborations with major pharmaceutical partners and academic institutions.